The CamSol method of rational design of protein mutants with enhanced solubility

Journal of Molecular Biology

Volumn 427, Issue 2, 2015, Pages 478-490

  Sormanni, Pietro ^a   Aprile, Francesco A ^a   Vendruscolo, Michele ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Protein aggregation; Protein solubility

Indexed keywords

AMINO ACID; AMYLOID BETA PROTEIN; MUTANT PROTEIN; PROTEIN; PROTEIN VARIANT; RECOMBINANT PROTEIN;

ACCURACY; ALZHEIMER DISEASE; ARTICLE; BIOLOGICAL ACTIVITY; CLONING; COST EFFECTIVENESS ANALYSIS; METHODOLOGY; MUTATION; NONHUMAN; PRIORITY JOURNAL; SCREENING; SOLUBILITY; CHEMICAL STRUCTURE; CHEMISTRY; CIRCULAR DICHROISM; COMPUTER SIMULATION; ESCHERICHIA COLI; GENETICS; MOLECULAR CLONING; PHYSICAL CHEMISTRY; PROCEDURES; PROTEIN CONFORMATION; PROTEIN ENGINEERING;

AMINO ACIDS; CIRCULAR DICHROISM; CLONING, MOLECULAR; COMPUTER SIMULATION; ESCHERICHIA COLI; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTANT PROTEINS; PHYSICOCHEMICAL PHENOMENA; PROTEIN CONFORMATION; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; SOLUBILITY;

EID: 84920766142     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2014.09.026     Document Type: Article

References (59)

1. Pavlou AK, Reichert JM. Recombinant protein therapeutics - Success rates, market trends and values to 2010. Nat Biotechnol 2004;22:1513-9.
2. Leader B, Baca QJ, Golan DE. Protein therapeutics: A summary and pharmacological classification. Nat Rev Drug Discov 2008;7:21-39.
3. Goodman M. Market watch: Sales of biologics to show robust growth through to 2013. Nat Rev Drug Discov 2009;8:837.
4. Carter PJ. Introduction to current and future protein therapeutics: A protein engineering perspective. Exp Cell Res 2011;317:1261-9.
5. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol 1994;12:433-55.
6. Sidhu SS. Phage display in pharmaceutical biotechnology. Curr Opin Biotechnol 2000;11:610-6.
7. Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005;23:1105-16.
8. Bradbury AR, Sidhu SS, Dübel S, McCafferty J. Beyond natural antibodies: The power of in vitro display technologies. Nat Biotechnol 2011;29:245-54.
9. Lee CC, Perchiacca JM, Tessier PM. Toward aggregation-resistant antibodies by design. Trends Biotechnol 2013;31:612-20.
10. Elvin JG, Couston RG, van der Walle CF. Therapeutic antibodies: Market considerations, disease targets and bioprocessing. Int J Pharm 2013;440:83-98.
11. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006;6:343-57.
12. Jespers L, Schon O, Famm K, Winter G. Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat Biotechnol 2004;22:1161-5.
13. Shire SJ. Formulation and manufacturability of biologics. Curr Opin Biotechnol 2009;20:708-14.
14. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: An update. Pharm Res 2010;27:544-75.
15. Perchiacca JM, Tessier PM. Engineering aggregation-resistant antibodies. Annu Rev Chem Biomol Eng 2012;3:263-86.
16. Balch WE, Morimoto RI, Dillin A, Kelly JW. Adapting proteostasis for disease intervention. Science 2008;319:916-9.
17. Ciryam P, Tartaglia GG, Morimoto RI, Dobson CM, Vendruscolo M. Widespread aggregation and neurodegenerative diseases are associated with supersaturated proteins. Cell Rep 2013;5:781-90.
18. Hartl FU, Bracher A, Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis. Nature 2011;475:324-32.
19. Dobson CM. Protein folding and misfolding. Nature 2003;426:884-90.
20. Ventura S, Villaverde A. Protein quality in bacterial inclusion bodies. Trends Biotechnol 2006;24:179-85.
21. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 2000;10:524-30.
22. Baneyx F, Mujacic M. Recombinant protein folding and misfolding in Escherichia coli. Nat Biotechnol 2004;22:1399-408.
23. Davis GD, Elisee C, Newham DM, Harrison RG. New fusion protein systems designed to give soluble expression in Escherichia coli. Biotechnol Bioeng 1999;65:382-8.
24. Arnau J, Lauritzen C, Petersen GE, Pedersen J. Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins. Protein Expression Purif 2006;48:1-13.
25. Sørensen HP, Mortensen KK. Soluble expression of recombinant proteins in the cytoplasm of Escherichia coli. Microb Cell Factories 2005;4:1.
26. Waldo GS. Genetic screens and directed evolution for protein solubility. Curr Opin Chem Biol 2003;7:33-8.
27. Aharoni A, Gaidukov L, Yagur S, Toker L, Silman I, Tawfik DS. Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc Natl Acad Sci USA 2004;101:482-7.
28. Frokjaer S, Otzen DE. Protein drug stability: A formulation challenge. Nat Rev Drug Discov 2005;4:298-306.
29. Famm K, Hansen L, Christ D, Winter G. Thermodynamically stable aggregation-resistant antibody domains through directed evolution. J Mol Biol 2008;376:926-31.
30. Jung S, Honegger A, Plückthun A. Selection for improved protein stability by phage display. J Mol Biol 1999;294:163-80.
31. Ladiwala ARA, Bhattacharya M, Perchiacca JM, Cao P, Raleigh DP, Abedini A, et al. Rational design of potent domain antibody inhibitors of amyloid fibril assembly. Proc Natl Acad Sci USA 2012;109:19965-70.
32. Perchiacca JM, Ladiwala ARA, Bhattacharya M, Tessier PM. Structure-based design of conformation- and sequence-specific antibodies against amyloid beta. Proc Natl Acad Sci USA 2012;109:84-9.
33. Rouet R, Lowe D, Christ D. Stability engineering of the human antibody repertoire. FEBS Lett 2014;588:269-77.
34. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci USA 2009;106:11937-42.
35. Chiti F, Stefani M, Taddei N, Ramponi G, Dobson CM. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 2003;424:805-8.
36. Tartaglia GG, Pawar AP, Campioni S, Dobson CM, Chiti F, Vendruscolo M. Prediction of aggregation-prone regions in structured proteins. J Mol Biol 2008;380:425-36.
37. Fernandez-Escamilla A-M, Rousseau F, Schymkowitz J, Serrano L. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol 2004;22:1302-6.
38. Wilkinson DL, Harrison RG. Predicting the solubility of recombinant proteins in Escherichia coli. Nat Biotechnol 1991;9:443-8.
39. Magnan CN, Randall A, Baldi P. Solpro: Accurate sequence-based prediction of protein solubility. Bioinformatics 2009;25:2200-7.
40. Smialowski P, Doose G, Torkler P, Kaufmann S, Frishman D. PROSO II - A new method for protein solubility prediction. FEBS J 2012;279:2192-200.
41. Agostini F, Vendruscolo M, Tartaglia GG. Sequence-based prediction of protein solubility. J Mol Biol 2012;421:237-41.
42. Wang X, Das TK, Singh SK, Kumar S. Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies. MAbs 2009;1:254.
43. Dudgeon K, Rouet R, Kokmeijer I, Schofield P, Stolp J, Langley D, et al. General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proc Natl Acad Sci USA 2012;109:10879-84.
44. Barthelemy PA, Raab H, Appleton BA, Bond CJ, Wu P, Wiesmann C, et al. Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains. J Biol Chem 2008;283:3639-54.
45. Pawar AP, Dubay KF, Zurdo J, Chiti F, Vendruscolo M, Dobson CM. Prediction of "aggregation-prone" and "aggregation-susceptible" regions in proteins associated with neurodegenerative diseases. J Mol Biol 2005;350:379-92.
46. Pechmann S, Levy ED, Tartaglia GG, Vendruscolo M. Physicochemical principles that regulate the competition between functional and dysfunctional association of proteins. Proc Natl Acad Sci USA 2009;106:10159-64.
47. Tsytlonok M, Sormanni P, Rowling PJ, Vendruscolo M, Itzhaki LS. Subdomain architecture and stability of a giant repeat protein. J Phys Chem B 2013;117:13029-37.
48. Trevino SR, Scholtz JM, Pace CN. Measuring and increasing protein solubility. J Pharm Sci 2008;97:4155-66.
49. Miklos AE, Kluwe C, Der BS, Pai S, Sircar A, Hughes RA, et al. Structure-based design of supercharged, highly thermoresistant antibodies. Chem Biol 2012;19:449-55.
50. Tan PH, Chu V, Stray JE, Hamlin DK, Pettit D, Wilbur DS, et al. Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility. Immunotechnology 1998;4:107-14.
51. Pantaloni D, Carlier M, Coue M, Lal A, Brenner S, Korn E. The critical concentration of actin in the presence of ATP increases with the number concentration of filaments and approaches the critical concentration of actin.ADP. J Biol Chem 1984;259:6274-83.
52. Aprile FA, Dhulesia A, Stengel F, Roodveldt C, Benesch JL, Tortora P, et al. Hsp70 oligomerization is mediated by an interaction between the interdomain linker and the substrate-binding domain. PLoS One 2013;8:e67961.
53. Huertas ML, Carrasco B. Calculation of hydrodynamic properties of globular proteins from their atomic-level structure. Biophys J 2000;78:719-30.
54. Arosio P, Barolo G, Müller-Späth T, Wu H, Morbidelli M. Aggregation stability of a monoclonal antibody during downstream processing. Pharm Res 2011;28:1884-94.
55. Šali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993;234:779-815.
56. Fiser A, Sali A. Modeller: Generation and refinement of homology-based protein structure models. Methods Enzymol 2003;374:461-91.
57. Wimley WC, White SH. Experimentally determined hydrophobicity scale for proteins at membrane interfaces. Nat Struct Biol 1996;3:842-8.
58. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, et al. Scalable molecular dynamics with NAMD. J Comput Chem 2005;26:1781-802.
59. Benkert P, Künzli M, Schwede T. QMEAN server for protein model quality estimation. Nucleic Acids Res 2009;37:W510-4.